论文部分内容阅读
多发性硬化(multiple sclerosis,MS)是中枢神经系统脱髓鞘疾病中最常见的自身免疫性疾病,其临床特点是病灶播散广泛,病程常表现为缓解-复发的脑脊髓炎,多伴有视神经损害。目前全世界患者约有250万人,以青、中年多见,女性居多。迄今这一疾病还无法治愈。富马酸二甲酯(dimethylfumarate,DMF)是一种治疗MS的新型口服药物,2013年被美国FDA批准用于临床治疗复发-缓解型MS。它可降低疾病的活动度,同时能减少复发-缓解型MF的复发。该文针对DMF在MS治疗中的应用及其作用机制进行简要阐述。
Multiple sclerosis (MS) is the most common autoimmune disease in demyelinating diseases of the central nervous system. Its clinical features are extensive spread of the disease, the course of which often manifests as remission encephalomyelitis, Optic nerve damage. At present, about 2.5 million patients worldwide are young and middle-aged, mostly women. So far this disease can not be cured. Dimethylfumarate (DMF) is a new oral drug used to treat MS. It was approved by the FDA in 2013 for the clinical treatment of relapsing-remitting MS. It reduces disease activity while reducing relapse-remitting MF recurrence. This article describes the application of DMF in MS treatment and its mechanism of action.